Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Background: For most patients with acute myeloid leukemia (AML) harboring a trisomy 8 an allogeneic hematopoietic stem cell transplantation (HSCT) is a suitable and recommended consolidation therapy. However, comparative outcome analyses between patients with and without trisomy 8 undergoing allogen...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Donata Backhaus, Madlen Jentzsch, Lara Bischof, Dominic Brauer, Christina Wilhelm, Julia Schulz, Georg-Nikolaus Franke, Wolfram Pönisch, Vladan Vucinic, Uwe Platzbecker, Sebastian Schwind
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
trisomy 8
AML
allogeneic HSCT
MRD
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/797cdbdae53349c79acd6c63e269a2f6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/797cdbdae53349c79acd6c63e269a2f6

Ejemplares similares